Quarter Horse
The New Year begins with a new partnership between Luitpold Pharmaceuticals’ Adequan® and the American Quarter Horse Association. Luitpold is the manufacturer of the well-known joint therapy product Adequan® (Polysulfated Glycosaminoglycan). Adequan® is now the official equine joint therapy of AQHA.
As AQHA’s newest Corporate Partner, Adequan® will be the title sponsor of the Adequan® Select World Championship Show, which is the world’s largest, single-breed world championship horse show open exclusively to amateur exhibitors age 50 and older. The company will also sponsor the AQHA World Championship Show and the Adequan® Derby Challenge, which is part of the Bank of America Racing Challenge Program.
“AQHA is the largest equine breed association, and this will give us a great opportunity to interact with all of the horse owners, trainers and riders that participate in the various disciplines,” said Allyn Mann, Senior Manager of Animal Health Divisions for Luitpold. “I am really excited to have the opportunity to attend the AQHA events and to get a little more involved in all aspects of the American Quarter Horse industry. I’m looking forward to the opportunity to educate AQHA members on joint health and how a product like Adequan® can really offer some great benefits to their animals that they love and enjoy. We’ve prided ourselves in the last five years on promoting education and then secondarily selling our products because we feel that an educated consumer will make the right choices in the best interest of their animals.”
Non-infectious arthritis and degenerative joint disease (DJD) are significant causes of poor performance and economic loss in athletic horses. In 1984, Luitpold founded its animal health division to develop and manufacture a treatment for DJD. The company developed Adequan® i.a. (Polysulfated Glycosaminoglycan), which obtained the approval of the Food and Drug Administration (FDA) for intra-articular injection in 1984. The efficacy of Adequan® i.a. (Polysulfated Glycosaminoglycan) won acclaim and became an asset to the field of veterinary medicine. When Adequan® i.m. (Polysulfated Glycosaminoglycan) was introduced in 1989, it offered the benefit of systemic treatment and a route of administration useful to a large group of equine veterinarians. The medication works in four ways by: blocking the damaging enzymes as they form, relieving the pain of inflammation, improving lubrication in the joints and inhibiting degeneration before cartilage damage can continue.
For more information on Adequan and Luitpold Pharmaceuticals visit www.Adequan.com.
The American Quarter Horse Association is the world’s largest single-breed equine registry and membership organization. Today, the Association that was founded in 1940 has more than 5 million American Quarter Horses registered worldwide and more than 320,000 AQHA members. For more information on AQHA, visit www.aqha.com.
AQHA news and information is a service of AQHA publications. For more information on The American Quarter Horse Journal, The American Quarter Horse Racing Journal or America’s Horse, visit www.aqha.com/magazines.
Top of Page
|
